Nancy Chavez Coleman
Family · San Antonio, TXNPI 1720666126
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 210 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,186 and has fallen 95.0% since, to $160 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $30.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- Dexcom, Inc.$650
- Mannkind Corporation$395
- Esperion Therapeutics, Inc.$387
- Xeris Pharmaceuticals, Inc.$317
- plus $2K from 21 others
What the payments were for
- Food & beverage$6,30698%
- Education$431%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $1,276 |
| AstraZeneca(2 entities) | 36 | $1,157 |
| Dexcom, Inc. | 16 | $650 |
| Mannkind Corporation | 6 | $395 |
| Esperion Therapeutics, Inc. | 4 | $387 |
| Xeris Pharmaceuticals, Inc. | 13 | $317 |
| Sanofi-aventis U.S. LLC | 11 | $261 |
| Amarin Pharma, Inc. | 12 | $235 |
| Cequr Corporation | 2 | $223 |
| Medtronic | 15 | $219 |
| Lilly USA, LLC | 12 | $189 |
| Zealand Pharma US, Inc. | 9 | $180 |
| Recordati_rare_diseases_inc. | 3 | $162 |
| Amgen | 9 | $155 |
| Radius Health, Inc. | 5 | $113 |
| Tandem Diabetes Care, Inc. | 2 | $112 |
| Boehringer Ingelheim | 4 | $67 |
| Corcept Therapeutics | 3 | $59 |
| Lifescan, Inc. | 4 | $49 |
| Ultragenyx Pharmaceutical Inc. | 2 | $46 |
| Nestle Healthcare Nutrition Inc. | 2 | $42 |
| Ipsen Biopharmaceuticals, Inc | 2 | $39 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Novartis | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Madrigal Pharmaceuticals | 1 | $14 |
| EUSA Pharma (US) LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$489
- NEXLIZET$374
- NEXLETOL$374
- Wegovy$242
- DEXCOM G6 TRANSMITTER$242
- Ozempic$238
- AFREZZA$208
- CeQur Simplicity$135
- RYBELSUS$125
- t:slim X2 Insulin Pump with Control-IQ$102
- Saxenda$101
How this compares
$6,408 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 235 | $262,023 |
| OzempicSemaglutide | 148 | $174,717 |
| MounjaroTirzepatide | 107 | $114,520 |
| JardianceEmpagliflozin | 48 | $61,400 |
| FarxigaDapagliflozin Propanediol | 25 | $25,515 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $20,319 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $13,176 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $10,270 |
| Novolog FlexpenInsulin Aspart | 32 | $8,874 |
| Humalog Kwikpen U-100Insulin Lispro | 22 | $5,906 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 37 | $4,970 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $3,728 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 16 | $3,478 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $3,339 |
| SynthroidLevothyroxine Sodium | 12 | $1,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $189 | $376,543342 claims |
| Novo NordiskOzempic | $1,276 | $174,717148 claims |
| Boehringer IngelheimJardiance | $67 | $61,40048 claims |
| AstraZenecaFarxiga | $1,157 | $25,51525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Febbie PhiriSan Antonio$31K
- Annette GantzSan Antonio$31K
- Renee ChisumSan Antonio$28K
- Thimios PartalasSan Antonio$27K
- David WeirDallas$959K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.